secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001558370-24-014186
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech subsidiary Journey Medical receives FDA approval for Emrosi to treat rosacea in adults
--------------------------------------------------------------------------------

- FDA approved Emrosi (Minocycline HCL ER 40mg) for inflammatory lesions of rosacea; Journey Medical to market it in U.S.
- Phase 3 trials met all endpoints; Emrosi showed statistically significant superiority over Oracea® 40mg and placebo.
- Initial supply expected late Q1 or early Q2 2025; developed with Dr. Reddy’s Laboratories.
- Journey Medical is a majority-controlled subsidiary of Fortress Biotech (FBIO).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024014186/0001558370-24-014186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024014186/fbio-20241104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer